Ubix Therapeutics, Inc.
http://en.ubixtrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ubix Therapeutics, Inc.
Stable Cash Flow, New Modalities Key To SK Bio’s Journey To Big, Balanced Biotech
South Korea's SK Biopharmaceuticals unveils a new long-term road map, or "financial story", which involves generating substantial cash flow and expansion into new modalities with the ultimate goal of becoming a “balanced, big biotech.”
TPD A Rising Option For Korean Pharma Seeking New Modalities
Highlighted by SK Biopharmaceuticals’ recent decision to acquire the US-based ProteoVant Sciences, Korean pharma firms are stepping up deals and collaborations in the hot TPD space, which is expected to continue to attract global investors and big pharma interest.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice